Roctavian基因治疗用于血友病A
本文综述了valoctocogene roxaparvovec(Roctavian)的临床开发历程,该药是首个获批的血友病A基因治疗药物,于2022年8月在欧洲附条件批准、2023年6月在美国获批。综述指出Roctavian治疗后FVIII表达逐年下降,与其他AAV血友病A基因治疗试验中观察到的稳定表达形成对比,下一代方法仍需开发才能实现稳定FVIII表达。
要点
- Roctavian是首个获批的血友病A基因治疗药物,2022年8月欧洲附条件批准、2023年6月美国获批。
- Roctavian治疗后FVIII表达出现逐年下降,机制尚未阐明。
- 其他AAV血友病A基因治疗试验中初始FVIII表达较低但保持稳定。
核心结论
- Roctavian的开发与获批是血友病A治疗领域的里程碑,但需下一代方法才能实现稳定FVIII表达并使止血正常化。
研究设计与样本
- 本文为综述,聚焦Roctavian的临床开发,其临床试验集合是迄今任何已获批AAV产品中最大的临床研究数据体。
主要发现
- Roctavian治疗后FVIII表达出现逐年下降,而其他AAV血友病A基因治疗试验中初始FVIII表达较低但保持稳定。
- 该FVIII表达逐年下降现象已在动物模型中定性重现,可能允许机制研究。
局限性
- Roctavian治疗后FVIII表达逐年下降的原因尚未阐明。
- 需要下一代方法才能实现血友病A基因治疗稳定FVIII表达并使止血正常化的承诺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
After successful efforts in adeno-associated virus (AAV) gene addition for hemophilia B gene therapy, the development of valoctocogene roxaparvovec (Roctavian; Biomarin) over the past decade represents a potential new hemophilia A (HA) treatment paradigm. Roctavian is the first licensed HA gene therapy that was conditionally approved in Europe in August 2022 and approved in the United States in June 2023. Beyond Roctavian, there are ongoing pivotal trials of additional AAV vectors for HA, others that are progressing through preclinical development or early-phase clinical trial, as well as non-AAV approaches in clinical development. This review focuses on the clinical development of Roctavian for which the collective clinical trials represent the largest body of work thus far available for any licensed AAV product. From this pioneering clinical development, several outstanding questions have emerged for which the answers will undoubtedly be important to the clinical adaptation of Roctavian and future efforts in HA gene therapy. Most notably, unexplained year-over-year declines in factor VIII (FVIII) expression after Roctavian treatment contrast with stable FVIII expression observed in other AAV HA gene therapy clinical trials with more modest initial FVIII expression. This observation has been qualitatively replicated in animal models that may permit mechanistic study. The development and approval of Roctavian is a landmark in HA therapeutics, although next-generation approaches are needed before HA gene therapy fulfills its promise of stable FVIII expression that normalizes hemostasis.
引用
- Samelson-Jones BJ, Small JC, George LA, et al. Roctavian gene therapy for hemophilia A. Blood Adv. 2024. PMID: 38991118. doi:10.1182/bloodadvances.2023011847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。